Articles

Novo wins UK approval as race to launch weight-loss pill intensifies

Novo Nordisk won UK approval for its oral Wegovy weight-loss pill, making the UK the first European market to allow access. The decision strengthens Novo’s lead in the oral GLP-1 race as Eli Lilly advances orforglipron.

AI in Drug Discovery Examples: What’s Changed Beyond Early Use Cases

AI in drug discovery examples now extend beyond target finding into trial design, patient stratification, and regulated evidence generation. For BD teams and investors, the key shift is from standalone tools to systems that can influence the full development chain.

Europe Drug Prices Face Pressure as U.S. Benchmarking Tightens

Europe drug prices are under fresh pressure as companies weigh how lower pricing in Europe could affect U.S. pricing power. The result may reshape launch sequencing, access strategy, and competitive positioning across major EU markets.

Federal Court Litigation on Reproductive Health: Rare Disease Implications

This analysis examines recent federal court litigation involving reproductive health and rights, with a specific focus on implications for rare disease drug development and regulatory pathways. It provides decision-useful insights for pharma business development teams, investors, and analysts tracking FDA policy changes.

EC nod for Chiesi Lojuxta for pediatric HoFH: what it means for pharma

The European Commission has expanded Lojuxta's indication to include children aged 5 years and older with homozygous familial hypercholesterolemia. This analysis covers the regulatory shift, implications for Chiesi's rare disease franchise, and what investors and BD teams should monitor next.

The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck

Data harmonization is the process of combining data across different sources and sites to enable comparison across studies. AI-driven tools are now transforming this critical bottleneck, reducing manual errors and accelerating clinical research.

European Cancer Guidelines Add Delcath Liver Therapy for Eye Melanoma

The ESMO-EURACAN clinical practice guidelines now include Delcath's CHEMOSAT hepatic delivery system as a recommended liver-directed therapy for metastatic uveal melanoma. This decision, supported by two Phase 3 trials, strengthens the therapy's regulatory and commercial positioning in Europe.

New EU Template for Clinical Trial Recruitment and Informed Consent: What Pharma Teams Need to Know

The European Medicines Agency (EMA) has introduced a new harmonised template for participant recruitment and informed consent procedures in clinical trials. This article explains the key changes, their impact on pharmaceutical companies, and answers frequently asked questions.

FDA Voucher Program Pause Urged: Rare Disease Policy Analysis

Drug companies and patient groups are urging the FDA to pause its commissioner's voucher program, citing concerns over political meddling in rare disease drug reviews. This analysis tracks the policy shift and its implications for pharma business development and investment teams.

Novel Muscle-Active Agents: A Regulatory Perspective on Sarcopenia

This article provides a regulatory perspective on the development of novel muscle-active agents for sarcopenia, focusing on myostatin and activin A inhibitors. It covers key biological targets, regulatory considerations, and implications for pharmaceutical teams.

Health News Round Up: Diabetes, Vaping, and Biologics – What Pharma Teams Need to Know

Recent research reveals a significant association between vaping and increased risk of prediabetes and type 2 diabetes. This roundup analyzes the implications for pharma teams monitoring diabetes drug development and market dynamics.

Staff Stick: A B2B Guide to the Dual Meaning and Pharma Context

This article clarifies the dual meaning of 'staff'—as a stick and as employees—and applies it to a competitive benchmarking analysis of EuropaBio's team structure for pharma analysts and BD teams.

Nika Pharmaceuticals Inc OTCQB NIKA June 2026 Update: Key Developments and Strategic Implications

Nika Pharmaceuticals Inc (OTCQB: NIKA) is in active investor discussions and reported a Q1 2026 net loss of $13,359 with only $1,530 cash, raising substantial doubt about its ability to continue as a going concern. This update provides a structured analysis for pharma business development teams and investors.

Japan Grants Orphan Status to QRX003 for Netherton Syndrome: Implications for Pharma Teams

Japan's MHLW has granted orphan drug designation to Quoin Pharmaceuticals' QRX003 for Netherton syndrome, a rare skin disorder with no approved treatment. This designation provides up to 10 years of market exclusivity and priority review, signaling a significant regulatory milestone for the candidate.

Moderna Stock Rises as EMA Committee Backs New RSV Vaccine: Key Implications for Investors and BD Teams

Moderna Inc. stock (MRNA) rose 5.9% after an EMA committee backed its new RSV vaccine candidate. This analysis explains what changed, why it matters for pharma BD and investors, and what to watch next.

데일리팜 리크루트: Vyloy (zolbetuximab) Reimbursement Progress and Market Implications for Gastric Cancer

Vyloy (zolbetuximab) has passed the HIRA Pharmacoeconomic Evaluation Subcommittee and is set for Drug Reimbursement Evaluation Committee review. This analysis covers the clinical evidence, regulatory milestones, and strategic implications for pharma stakeholders.

Florian Lordick Elected ESMO President 2029–2030: What Pharma Teams Should Watch

Professor Florian Lordick has been elected President of the European Society for Medical Oncology (ESMO) for the 2029–2030 term. This analysis outlines the timeline, Lordick's background, and strategic implications for pharma teams tracking ESMO's evolving priorities.

From Approval to Access: Europe’s Next Health Imperative for Pharma

Despite EMA approvals, patients across Europe face delayed or no access to new medicines. This analysis examines the systemic barriers, the EU Pharma Package response, and the strategic implications for European pharma companies and investors.

Lilly to Spotlight Growing Hematology Portfolio at 2026 EHA Annual Meeting: Key Data and Strategic Implications

Lilly will present positive Phase 3 BRUIN CLL-322 results at the 2026 EHA Annual Meeting, comparing pirtobrutinib plus venetoclax and rituximab against venetoclax and rituximab. The presentation underscores Lilly's expanding hematology portfolio, bolstered by recent acquisitions of Ajax Therapeutics and Kelonia Therapeutics.

BBIA Joins EuropaBio: Strengthening the Bio-Based Economy for Pharma and Industry

The Bio-based and Biodegradable Industries Association (BBIA) has joined EuropaBio, Europe's largest biotechnology industry group. This move strengthens advocacy for the industrial bioeconomy, with implications for pharma companies investing in bio-based materials and sustainable packaging.